Treatment of cough for a long time with Unani medicine Laooq-e-Unsul

Phase 3

Not yet recruiting

• Conditions: Cough,

• Registration Number: CTRI/2024/09/073895
• Lead Sponsor: Central Council for Research in Unani Medicine CCRUM New Delhi

Brief Summary

This study is designed as a multi centric open trial in patients with **Sual-e-Muzmin (Chronic Cough)**. After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria.  The patients will be assessed clinically at 1st, 2nd and 3rd week for 4weeks. This includes subjective assessment of general well being and physical examination. The total duration of treatment will be 4weeks. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.

**Composition of****Laooq-e-Unsul****:**

| | | | |

| --- | --- | --- | --- |

|**S.No.**

**Name of the Ingredient**

**Botanical/ English name**

**Quantity**

|

Unsul Biryan

*Urginea indica* (Roxb.) Kunth

10 g

|

Beikh-e-Irsa

*Iris ensata* Thunb.

35 g

|

Farasiyun/tagar

*Valeriana  jatamansi*

5 g

|

Zufa Khushk

*Hyssopus officinalis Linn.*

5 g

|

Qand-e-Safaid

*Saccharum officianale*

Q.S.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-09-16

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

• Patients of either sex in the age group of 18-60 2.
• Sual-e-Muzmin (Chronic cough) of more than 8 weeks duration.

Exclusion Criteria

• Acute Upper Respiratory Tract Infections (URI or URTI) 2.
• Acute Lower Respiratory Tract Infections (LRI or LRTI) including pneumonia, lung abscess, and acute bronchitis.
• Chronic obstructive airway disease (COAD) including chronic bronchitis and emphysema.
• History of Bronchiectasis, pulmonary tuberculosis, pulmonary edema, interstitial pulmonary fibrosis 5.
• Known cases of Tumors of larynx, bronchi, and lungs 6.
• Drug history of ACE Inhibitors 7.
• Known cases of Diabetes Mellitus, Hypertension 8.
• Known cases of severe hepatic, renal or cardiac ailments 9.
• H/o addiction (smoking, alcohol, drugs) 10.
• Pregnant and lactating women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The efficacy of the study drugs will be assessed on the basis of Cough Severity Index	At 1st, 2nd and 3rd week

Secondary Outcome Measures

Name	Time	Method
Haematological & biochemical assessment for safety assessment i.e. CBC, LFT, KFT, Urine Routine & microscopic examination	At baseline and at the end of treatment for 4 weeks

Trial Locations

Locations (2)

National Research Institute of Unani Medicine for Skin Disorders; 🇮🇳 Hyderabad, TELANGANA, India

Regional Institute of Unani Medicine (RRIUM); 🇮🇳 Aligarh, UTTAR PRADESH, India

National Research Institute of Unani Medicine for Skin Disorders

🇮🇳Hyderabad, TELANGANA, India

Dr Mohd Anis Ansari

Principal investigator

9044124159

mohdanees120393@gmail.com